Palforzia Peanut Allergy Immunotherapy: Aimmune CEO On REMS Restrictions, Manufacturing
Aimmune CEO Jayson Dallas tells the Pink Sheet how physicians and patients are being certified to use Palforzia and how the product's food-based manufacturing process is actually an advantage.
You may also be interested in...
Since Palforzia likely will be the only peanut allergy drug on market for some time, Nestle announces it will pay about $2.6bn to acquire the 80% of Aimmune it doesn’t own.
The latest US FDA approvals and actions from the Pink Sheet’s US FDA Performance Tracker.
The year began with an unusually low number of CRLs, but a recent burst of non-approval actions suggests a COVID-19 effect.